[go: up one dir, main page]

SG11201912267SA - Nicotinamide riboside derivatives and their uses - Google Patents

Nicotinamide riboside derivatives and their uses

Info

Publication number
SG11201912267SA
SG11201912267SA SG11201912267SA SG11201912267SA SG11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA
Authority
SG
Singapore
Prior art keywords
nicotinamide riboside
riboside derivatives
derivatives
nicotinamide
riboside
Prior art date
Application number
SG11201912267SA
Other languages
English (en)
Inventor
Gangadhara Ganapati
Atignal Shankara Rao Arvind
Original Assignee
Gangadhara Ganapati
Atignal Shankara Rao Arvind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gangadhara Ganapati, Atignal Shankara Rao Arvind filed Critical Gangadhara Ganapati
Publication of SG11201912267SA publication Critical patent/SG11201912267SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201912267SA 2017-06-19 2018-06-19 Nicotinamide riboside derivatives and their uses SG11201912267SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521717P 2017-06-19 2017-06-19
PCT/US2018/038201 WO2018236814A2 (fr) 2017-06-19 2018-06-19 Dérivés de nicotinamide riboside et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201912267SA true SG11201912267SA (en) 2020-01-30

Family

ID=62875307

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912267SA SG11201912267SA (en) 2017-06-19 2018-06-19 Nicotinamide riboside derivatives and their uses

Country Status (4)

Country Link
US (1) US11286274B2 (fr)
EP (1) EP3642214A2 (fr)
SG (1) SG11201912267SA (fr)
WO (1) WO2018236814A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200138921A1 (en) * 2017-06-23 2020-05-07 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
WO2019089417A1 (fr) * 2017-10-30 2019-05-09 Elysium Health, Inc. Méthodes et compositions pour le traitement de la fibrose kystique
US20200384004A1 (en) * 2017-12-01 2020-12-10 Elysium Health, Inc. Methods and compositions for treating glaucoma
CN108841781A (zh) * 2018-06-13 2018-11-20 延边大学 藏红花素在提高猪卵母细胞抗氧化能力及卵裂率中的应用
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
US11266696B2 (en) * 2019-01-18 2022-03-08 Americord Registry Llc Method of treating stem cells with NAD
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
WO2020176445A1 (fr) * 2019-02-26 2020-09-03 Universitat De Valencia-Estudi General Méthodes et compositions pour le traitement de maladies des motoneurones
WO2020190703A1 (fr) * 2019-03-21 2020-09-24 Elysium Health, Inc. Méthodes pour le traitement de plaies
US20220125814A1 (en) * 2019-03-21 2022-04-28 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
EP3946306A2 (fr) * 2019-03-29 2022-02-09 Société des Produits Nestlé S.A. Compositions et méthodes d'augmentation de la fonction des lymphocytes t
WO2020245187A1 (fr) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Nicotinamide ribosides réduits pour traiter ou prévenir une maladie rénale
EP3980028A1 (fr) * 2019-06-05 2022-04-13 Société des Produits Nestlé S.A. Nicotinamide ribosides réduits pour traiter/prévenir une maladie de muscle squelettique
BR112021021726A2 (pt) * 2019-06-05 2021-12-28 Nestle Sa Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doença hepática
WO2020257283A1 (fr) * 2019-06-18 2020-12-24 Mitopower Llc Composés nicotinyl riboside et leurs utilisations
CA3145870A1 (fr) * 2019-07-26 2021-02-04 Hampar L. Karageozian Peptides pour le traitement de la degenerescence maculaire non-exsudative et d'autres troubles de l'?il
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
FR3102058A1 (fr) * 2019-10-18 2021-04-23 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
IL292350A (en) 2019-10-30 2022-06-01 Perfuse Therapeutics Inc Treatment of ocular diseases using endothelin receptor antagonists
CN113490676A (zh) * 2019-11-19 2021-10-08 清华大学 Nmn衍生物的合成方法和nmn及其衍生物的医学应用
US20230096443A1 (en) * 2019-12-20 2023-03-30 Nuvamid Sa Novel nicotinamide di-nucleotide derivatives and use thereof
IL294873A (en) 2020-02-06 2022-09-01 Perfuse Therapeutics Inc Preparations for the treatment of eye diseases
EP4114429A2 (fr) * 2020-03-06 2023-01-11 Allegro Pharmaceuticals, LLC Traitements pour améliorer ou diminuer la dégradation de la fonction mitochondriale
WO2021180740A1 (fr) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions et procédés faisant appel à du nicotinamide riboside réduit pour la prévention et le traitement de maladies et d'affections pulmonaires
WO2021180741A1 (fr) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions contenant un nicotinamide riboside et méthodes destinées à la prévention et au traitement des maladies et affections pancréatiques
FR3108502B1 (fr) * 2020-03-27 2022-09-23 Nuvamid Sa Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes
US20230117880A1 (en) * 2020-03-30 2023-04-20 Oriental Yeast Co., Ltd. Chromosome-stabilizing agent for stem cells
CN111454311B (zh) 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
US20210353656A1 (en) * 2020-05-12 2021-11-18 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and histamine h2 receptor antagonists for viral infections
EP3949964A1 (fr) * 2020-08-06 2022-02-09 Nuvamid SA Combinaison de dérivés de nicotinamide mononucléotidique et d'autres agents thérapeutiques pour leur utilisation dans le traitement des infections virales
WO2022029275A1 (fr) * 2020-08-06 2022-02-10 Nuvamid Sa Combinaison de dérivés de nicotinamide mononucléotide et d'autres agents thérapeutiques destinée à être utilisée dans le traitement d'infections à coronavirus et de la covid-19
CN112500445B (zh) * 2020-12-04 2022-11-29 黄冈鲁班药业股份有限公司 β-烟酰胺核糖的制备方法
CN113274363B (zh) * 2021-04-29 2023-02-10 珠海润都制药股份有限公司 一种吲达帕胺制剂
EP4329753A4 (fr) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. Compositions pharmaceutiques et systèmes d'administration intravitréenne de médicament pour le traitement de maladies oculaires
CA3224544A1 (fr) * 2021-06-18 2022-12-22 Mitopower Llc Traitement de troubles lies a l'immunite, de troubles renaux, de troubles hepatiques, de troubles hemolytiques et de troubles lies au stress oxydatif a l'aide de nrh, narh et de leurs derives reduits
WO2022269064A1 (fr) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Traitement d'augmentation de nad pour la maladie de parkinson
EP4440590A4 (fr) * 2021-12-01 2025-11-12 Univ Florida Approche thérapeutique combinatoire pour l'ataxie de friedreich
CN115232184B (zh) * 2021-12-06 2024-07-05 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物及其药物组合物和用途
CN118922189A (zh) * 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
WO2024050120A2 (fr) * 2022-09-02 2024-03-07 The Regents Of The University Of California Combinaisons de nicotinamide-riboside et de ptérostilbène pour traiter l'arthrose
WO2024123296A1 (fr) * 2022-12-07 2024-06-13 Atatürk Üni̇versi̇tesi̇ Rektörlüğü Bi̇li̇msel Araştirma Projeleri̇ (Bap) Koordi̇nasyon Bi̇ri̇mi̇ Composé contenant du nicotinamide riboside pour inhiber la formation de kystes et induire l'ovulation dans le syndrome des ovaires polykystiques
WO2025024484A1 (fr) * 2023-07-25 2025-01-30 Duke University Compositions et méthodes pour traiter le cancer du sang
WO2025059572A1 (fr) * 2023-09-15 2025-03-20 University Of Washington Réparation d'adn à travers l'administration nanothérapeutique de nad+ et de précurseurs de nad+

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190079A (en) 1966-07-29 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
CA2530407A1 (fr) 2003-07-23 2005-02-03 The Regents Of The University Of California Combinaisons d'amplificateurs de penetration pour administration transdermique
EP1723227A4 (fr) 2004-02-10 2007-09-19 Dartmouth College Compositions de nicotinamide riboside kinase et procedes d'utilisation
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070099830A1 (en) * 2005-04-21 2007-05-03 Massachusetts Institute Of Technology Sirt4 activities
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP3369738B1 (fr) 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Procédé de préparation de nicotinates de riboside et de nicotinamide-beta-riboside
JP2011518200A (ja) 2008-04-22 2011-06-23 メルク フロスト カナダ リミテツド ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての新規な置換複素環式芳香族化合物
EP2307378A1 (fr) 2008-06-18 2011-04-13 Pfizer Limited Dérivés de nicotinamide
US20140065099A1 (en) * 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
RU2015143836A (ru) 2013-03-15 2017-04-27 Нусерт Сайенсиз, Инк. Лейцин и никотиновая кислота для снижения уровня липидов
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
CN105873937A (zh) 2013-10-30 2016-08-17 可劳迈戴斯有限公司 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
CN106715454B (zh) 2014-07-24 2020-06-16 格雷斯公司 烟酰胺核苷的结晶形式
EP2979706A1 (fr) * 2014-07-30 2016-02-03 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Procédés pour le traitement du cancer du foie ou du pancréas
WO2016122832A1 (fr) 2015-01-30 2016-08-04 Natural Formulations Compositions, méthodes thérapeutiques et prophylactiques pour le traitement de maladies neurodégénératives et de lésions cérébrales
FI3268379T3 (fi) 2015-03-09 2023-12-15 Grace W R & Co Nikotiiniamidiribosidin kiteinen muoto
BR112017019696A2 (pt) 2015-03-16 2018-09-04 ChromaDex Inc. composto e usos de um composto
AU2016271481A1 (en) 2015-06-04 2017-12-14 Chromadex, Inc. Selective solvent free phosphorylation
WO2017011788A1 (fr) * 2015-07-15 2017-01-19 Cornell University Synthèses, activités et procédés d'utilisation de dérivés du dihydronicotinamide riboside
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
IL299824B2 (en) 2015-10-07 2024-02-01 Huizenga Joel Resetting biological pathways for defending against and repairing deterioration from human aging
WO2017079195A1 (fr) 2015-11-02 2017-05-11 Mitobridge, Inc. Nicotinamide riboside et dérivés de nicotinamide mononucléotidique utiles dans les traitements de maladies associées aux mitochondries
WO2017109195A1 (fr) 2015-12-24 2017-06-29 Amazentis Sa Compositions comprenant un riboside de nicotinamide et une urolithine
AU2017232930B2 (en) 2016-03-16 2021-03-25 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
ES2981479T3 (es) 2016-04-14 2024-10-09 Chromadex Inc Fórmula para lactantes que comprende ribósido de nicotinamida
NZ747693A (en) 2016-04-20 2023-07-28 Chromadex Inc Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
WO2017218580A1 (fr) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Procédés synthétiques pour la préparation de nicotinamide riboside et de composés apparentés
EP3478297A1 (fr) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de cardiomyopathies
GB2553001A (en) 2016-08-19 2018-02-21 The Queen's Univ Of Belfast Lactone intermediates of nicotinamide riboside and nicotinate riboside
CN109982706A (zh) 2016-08-22 2019-07-05 益力舒健康公司 用于治疗神经退行性病症的烟酰胺核苷和紫檀芪的组合物和方法
WO2018089830A1 (fr) 2016-11-11 2018-05-17 The Queen's University Of Belfast Synthèses efficaces et évolutives de nicotinoyle ribosides et de nicotinoyle ribosides réduits, de leurs dérivés modifiés, de leurs analogues phosphorylés, de leurs conjugués avec de l'adénylyle dinucléotide et de nouvelles formes cristallines de ceux-ci
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CN110769834A (zh) 2017-03-17 2020-02-07 益力舒健康公司 用于治疗或预防肝损伤的烟酰胺核苷

Also Published As

Publication number Publication date
US11286274B2 (en) 2022-03-29
EP3642214A2 (fr) 2020-04-29
WO2018236814A2 (fr) 2018-12-27
WO2018236814A3 (fr) 2019-02-07
US20180362570A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SG11201912267SA (en) Nicotinamide riboside derivatives and their uses
ZA201801196B (en) Nicotinamide mononucleotide derivatives and their uses
GB2590198B (en) N4-hydroxycytidine derivatives and anti-viral uses related thereto
ZA201808131B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
ZA201706918B (en) Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
IL253656A0 (en) Mono- and polyazanephthalene modified histories and their use
IL258081B (en) Benzimidazole history and their use
EP3268362A4 (fr) Pyridines substituées et leurs utilisations
ZA201703768B (en) Fgf21 derivatives and uses thereof
IL259150B (en) Pyrimidine derivative and use thereof
IL273839A (en) Benzimidazole derivatives and their uses
HUE057328T2 (hu) Aminopiridin származékok és szelektív ALK-2 gátlóként való alkalmazásuk
GB2577419B (en) Lipo-glycopeptide cleavable derivatives and uses thereof
IL274722A (en) History of pyridinones and their use as selective inhibitors of ALK-2
SG11202008543RA (en) Pyrrolidineamide derivatives and uses thereof
EP3263550A4 (fr) Dérivés d'aniline et leurs utilisations
IL275211A (en) Fast and flexible segment chains - division
HK40007022A (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
HK40013318A (en) N-acylethanolamide derivatives and uses thereof
HK1247146A1 (en) Substituted mono- and polyazanaphthalene derivatives and their use